Clarifications regarding bumetanide for neonatal seizures.

Kevin J Staley

Journal: Epilepsia 2022;63(7):1863-1867

PMID: 35524444

Free Full Text on PubMed Central View on PubMed

Abstract

A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity. Concerns regarding bumetanide as an adjunctive anticonvulsant are addressed here. An adequately powered multi-institutional trial is needed to accurately determine efficacy.

Address: Neurology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

DOI: 10.1111/epi.17278

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/commoninfantandnewbornprob...

Subscription / membership required

Full Text Sources:

MeSH Terms: Bumetanide, Epilepsy, Humans, Infant, Newborn, Infant, Newborn, Diseases, Seizures, Sodium Potassium Chloride Symporter Inhibitors, Solute Carrier Family 12, Member 2